OGN - Organon & Co logo

OGN

Organon & Co

Organon & Co. develops women's health solutions through prescription therapies and medical devices, offering contraceptives, fertility treatments, and products for various medical conditions, including respiratory and cardiovascular issues, to healthcare providers globally.

โš•๏ธ Healthcare NYSE Listed 2021 $ USD
$1,000 invested 5 years ago โ†’$500today

Score Overview

1 Year
Score
Net Growth11.76%
Net TrendGrew
Net Income Consistencyโ€”
Rev Growth-1.43%
Rev TrendShrank
Revenue Consistencyโ€”
5 Years
Score3.9
Net Growth-84.53%
Net Trend40%
Net Income Consistencyโ€”
Rev Growth-2.81%
Rev Trend40%
Revenue Consistencyโ€”
All Time
Score
Net Growth-84.53%
Net Trend40%
Net Income Consistency
Rev Growth-2.81%
Rev Trend40%
Revenue Consistency

See the full market ranking โ†’

Organon & Co fundamental performance

Across Organon & Co's full reported history, from 2021 to 2025, revenue declined from $ 6.30B to $ 6.21B and net income declined from $ 1.35B to $ 187M. Revenue increased in 40% of the years measured; net income in 40%.

Organon & Co currently holds a 5-year HDB Score of 3.9 out of 10. How the HDB Score is calculated.

Net Income x Stock Price

Historical Returns

Historical Returns
PeriodPriceReturn
Last Price2026-08-12
$ 13.66โ€”
1 Year2025-08-12
$ 8.9752.27%
5 Years2021-08-12
$ 27.30-49.96%
All Time2021-06-02
$ 28.74-52.46%

Prices are split & dividend adjusted. All values are reported in USD.

Fundamental Data

Year
2026$ 6.12B$ 209M$ 1.13B
2025$ 6.21B$ 187M$ 574M
2024$ 6.40B$ 864M$ 675M
2023$ 6.26B$ 1.02B$ 693M
2022$ 6.17B$ 917M$ 706M
IPO2021$ 6.30B$ 1.35B$ 737M

Explore beyond OGN

You're looking at Organon & Co. Members apply the same fundamental framework across all 3,860 companies we cover.

$99/year $149 founding price

Unlock Holder Dashboard

30-day money-back guarantee.

Explore other companies